We are testing a new drug, SNDX-5613, combined with intensive chemotherapy for patients with AML who have certain genetic changes. The goal is to see if this combination improves treatment outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
Acute Myeloid Leukemia (AML) is a fast-growing cancer of the blood and bone marrow that results in the overproduction of immature white blood cells, leading to symptoms like fatigue, frequent infections, and easy bruising or bleeding.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
